Iron accelerates MDS progression
In this issue of Blood, Antypiuk et al, utilizing a murine model, demonstrate that iron overload (IOL), accumulated via a
patient
How I Treat Higher-Risk MDS with Alain Mina, Rami S. Komrokji
FDA Approves Axatilimab in 9 Mg and 22 Mg Vial Sizes for GVHD
Axatilimab-csfr (Niktimvo), a CSF-1R–targeting agent that reduces the drivers of inflammation and fibrosis, has been approved by the FDA in 9 mg and 22 mg vial sizes to treat adult and pediatric patients with
COMMANDS: Long-Term Analysis, Changes in RBC Transfusion Burden, Hemoglobin Levels and ELEMENTS Trial
Panelists discuss how long-term analysis of the ELEMENTS trial reveals significant improvements in red blood cell (RBC) transfusion burden and
2025 Kansas City Patient and Family Conference
Here are links to the conference sessions from the 2025 Kansas City Patient and Family Conference:
Event Date:
Fri, 04/25/2025 - 5:30pm (EDT) to Sat, 04/26/2025 - 3:30pm (EDT)
Bone Marrow Disease(s):
Conference Event Type:
2025 Rockville Patient and Family Conference
The 2025 Patient and Family Conference in Rockville, MD was held on March 8, 2025.
Below are links to conference session recordings in full.
Aplastic Anemia and Transplant
Event Date:
Sat, 03/08/2025 - 8:30am (EST)
Bone Marrow Disease(s):
Conference Event Type:
MDS and Keeping Hope - Donna's Story
Donna Gilbride explains her journey through diagnosis and treatment with MDS, or Myelodysplastic Syndromes.
Listen or read the transcript below.
Long, Hard, Road to Diagnosis - Shaquilla's Story
Shaquilla Gordon explains her journey with the bone marrow failure condition called PNH, or Paroxysmal Nocturnal Hemoglobinuria. Listen or read the transcript below.
Putting Treatment Behind Him: Webb's Journey through Aplastic Anemia
Person's Name:
Webb Kosich
Webb was in university, playing soccer, when he started noticing a rash and breathlessness during a run. He’d never had either symptom, particularly since he was in such good shape, playing soccer since the age of three.
Bone Marrow Disease(s):
Content source: